Sialic acids in cancer biology and immunity

Glycobiology

Volumn 26, Issue 2, 2015, Pages 111-128

  Pearce, Oliver M T ^a   Läubli, Heinz ^b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

N gycolyl neuraminic acid; selectin; sialidase; sialyltransferase; Siglec; tumor immunology

Indexed keywords

GLYCAN; MUCIN 1; N ACETYLNEURAMINIC ACID; N GLYCOLOYLNEURAMINIC ACID; SELECTIN; SIALIC ACID; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIALIDASE; SIALYLTRANSFERASE; SIALIC ACID DERIVATIVE;

ACETYLATION; ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; COLORECTAL CARCINOMA; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; GLYCOSYLATION; HUMAN; IMMUNE EVASION; MALIGNANT TRANSFORMATION; METASTASIS; NEUROBLASTOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; IMMUNOLOGY; METABOLISM;

ANIMALS; HUMANS; IMMUNE EVASION; SIALIC ACID BINDING IMMUNOGLOBULIN-LIKE LECTINS; SIALIC ACIDS; TUMOR MICROENVIRONMENT;

EID: 84960454276     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv097     Document Type: Article

References (227)

1. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, SammarM, et al. 1997. CD24, amucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 89:3385-3395.
2. Alfonso S, Valdes-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernandez M, Viada CE, Mendoza IC, Guerra PP, Garcia E, et al. 2014. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res. 20:3660-3671.
3. Ali SR, Fong JJ, Carlin AF, Busch TD, Linden R, Angata T, Areschoug T, Parast M, Varki N, Murray J, et al. 2014. Siglec-5 and Siglec-14 are polymorphic paired receptors that modulate neutrophil and amnion signaling responses to group B Streptococcus. J Exp Med. 211:1231-1242.
4. Amon R, Reuven EM, Leviatan Ben-Arye S, Padler-Karavani V. 2014. Glycans in immune recognition and response. Carbohydr Res. 389:115-122.
5. Angata T. 2006. Molecular diversity and evolution of the Siglec family of cellsurface lectins. Mol Divers. 10:555-566.
6. Angata T, Hayakawa T, YamanakaM, Varki A, NakamuraM. 2006. Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J. 20:1964-1973.
7. Angata T, Nakata D, Matsuda T, Kitajima K, Troy FA II. 1999. Biosynthesis of KDN (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid). Identification and characterization of a KDN-9-phosphate synthetase activity from trout testis. J Biol Chem. 274:22949-22956.
8. Angata K, Suzuki M, McAuliffe J, Ding Y, Hindsgaul O, Fukuda M. 2000. Differential biosynthesis of polysialic acid on neural cell adhesion molecule (NCAM) and oligosaccharide acceptors by three distinct alpha 2,8-sialyltransferases, ST8Sia IV (PST), ST8Sia II (STX), and ST8Sia III. J Biol Chem. 275:18594-18601.
9. Angata T, Varki A. 2002. Chemical diversity in the sialic acids and related alpha-keto acids: An evolutionary perspective. Chem Rev. 102:439-469.
10. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, et al. 2003. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA. 100:14205-14210.
11. Banda K, Gregg CJ, Chow R, Varki NM, Varki A. 2012. Metabolism of vertebrate amino sugars with N-glycolyl groups: Mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid. J Biol Chem. 287:28852-28864.
12. Bardor M, Nguyen DH, Diaz S, Varki A. 2005. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 280:4228-4237.
13. Basu SS, Basu M, Li Z, Basu S. 1996. Characterization of two glycolipid: Alpha 2-3sialyltransferases, SAT-3 (CMP-NeuAc:nLcOse4Cer alpha 2-3sialyltransferase) and SAT-4 (CMP-NeuAc:GgOse4Cer alpha 2-3sialyltransferase), from human colon carcinoma (Colo 205) cell line. Biochemistry. 35:5166-5174.
14. Berger J, Yaneva H, Antoine B. 1969. [Application of immunofluorescence to renal pathology. II. Immunohistochemical study of glomerular lesions]. J Urol Nephrol (Paris). 75:269-281.
15. Bergfeld AK, Pearce OM, Diaz SL, Lawrence R, Vocadlo DJ, Choudhury B, Esko JD, Varki A. 2012. Metabolism of vertebrate amino sugars with N-glycolyl groups: Incorporation of N-glycolylhexosamines into mammalian glycans by feeding N-glycolylgalactosamine. J Biol Chem. 287: 28898-28916.
16. Bergfeld AK, Pearce OM, Diaz SL, Pham T, Varki A. 2012. Metabolism of vertebrate amino sugars with N-glycolyl groups: Elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid. J Biol Chem. 287:28865-28881.
17. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. 1996. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med. 183: 581-587.
18. Bigi A, Morosi L, Pozzi C, Forcella M, Tettamanti G, Venerando B, Monti E, Fusi P. 2010. Human sialidase NEU4 long and short are extrinsic proteins bound to outer mitochondrial membrane and the endoplasmic reticulum, respectively. Glycobiology. 20:148-157.
19. Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM. 2011. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 13:R25.
20. Blixt O, Collins BE, van den Nieuwenhof IM, Crocker PR, Paulson JC. 2003. Sialoside specificity of the siglec family assessed using novel multivalent probes: Identification of potent inhibitors of myelin-associated glycoprotein. J Biol Chem. 278:31007-31019.
21. Bochner BS, Zimmermann N. 2015. Role of siglecs and related glycan-binding proteins in immune responses and immunoregulation. J Allergy Clin Immunol. 135:598-608.
22. Boligan KF, Mesa C, Fernandez LE, von Gunten S. 2015. Cancer intelligence acquired (CIA): Tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci. 72:1231-1248.
23. Bonardi D, Papini N, Pasini M, Dileo L, Orizio F, Monti E, Caimi L, Venerando B, Bresciani R. 2014. Sialidase NEU3 dynamically associates to different membrane domains specifically modifying their ganglioside pattern and triggering Akt phosphorylation. PLoS ONE. 9:e99405.
24. Bondar T, Medzhitov R. 2013. The origins of tumor-promoting inflammation. Cancer Cell. 24:143-144.
25. Bonten E, van der Spoel A, Fornerod M, Grosveld G, d'Azzo A. 1996. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 10:3156-3169.
26. Borsig L. 2007. Antimetastatic activities of modified heparins: Selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost. 33:540-546.
27. Borsig L, Vlodavsky I, Ishai-Michaeli R, Torri G, Vismara E. 2011. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase. Neoplasia. 13:445-452.
28. Borsig L, Wang L, Cavalcante MC, Cardilo-Reis L, Ferreira PL, Mourao PA, Esko JD, Pavao MS. 2007. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem. 282:14984-14991.
29. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. 2001. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 98:3352-3357.
30. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. 2002. Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA. 99:2193-2198.
31. Borys MC, Linzer DI, Papoutsakis ET. 1993. Culture pH affects expression rates and glycosylation of recombinant mouse placental lactogen proteins by Chinese hamster ovary (CHO) cells. Biotechnology (NY). 11:720-724.
32. Bos PD, Zhang XH, Nadal C, ShuW, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, et al. 2009. Genes that mediate breast cancer metastasis to the brain. Nature. 459:1005-1009.
33. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O. 2004. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 114:1714-1725.
34. Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor-Papadimitriou J. 1995. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 233:607-617.
35. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. 1997. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer. 71:612-619.
36. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, Miles D, Taylor-Papadimitriou J. 1999. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 9:1307-1311.
37. Burdick MM, Bochner BS, Collins BE, Schnaar RL, Konstantopoulos K. 2001. Glycolipids support E-selectin-specific strong cell tethering under flow. Biochem Biophys Res Commun. 284:42-49.
38. Burdick MM, McCaffery JM, Kim YS, Bochner BS, Konstantopoulos K. 2003. Colon carcinoma cell glycolipids, integrins, and other glycoproteins mediate adhesion toHUVECs under flow. Am J Physiol Cell Physiol. 284:C977-C987.
39. Cabezas JA. 1991. Some questions and suggestions on the type references of the official nomenclature (IUB) for sialidase(s) and endosialidase. Biochem J. 278(Pt 1):311-312.
40. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. 2004. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 104:397-401.
41. Carlin AF, Chang YC, Areschoug T, Lindahl G, Hurtado-Ziola N, King CC, Varki A, Nizet V. 2009. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med. 206:1691-1699.
42. Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood. 113:3333-3336.
43. Chang YC, Nizet V. 2014. The interplay between Siglecs and sialylated pathogens. Glycobiology. 24:818-825.
44. Chen GY, Tang J, Zheng P, Liu Y. 2009. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722-1725.
45. Chen W, Xiang J, Chen DF, Ni BB, Chen H, Fan XJ, Wang PN, Song SX, Fang LK, Xiao HY, et al. 2013. Screening for differentially methylated genes among human colorectal cancer tissues and normal mucosa by microarray chip. Mol Biol Rep. 40:3457-3464.
46. Cheresh DA, Reisfeld RA, Varki AP. 1984. O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science. 225:844-846.
47. Cheresh DA, Varki AP, Varki NM, Stallcup WB, Levine J, Reisfeld RA. 1984. A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem. 259:7453-7459.
48. Cheung IY, Vickers A, Cheung NK. 2006. Sialyltransferase STX (ST8SiaII): A novel molecular marker of metastatic neuroblastoma. Int J Cancer. 119:152-156.
49. Clark MC, Baum LG. 2012. T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci. 1253:58-67.
50. Comelli EM, Amado M, Lustig SR, Paulson JC. 2003. Identification and expression of Neu4, a novel murine sialidase. Gene. 321:155-161.
51. Corfield AP, Myerscough N, Warren BF, Durdey P, Paraskeva C, Schauer R. 1999. Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence. Glycoconj J. 16:307-317.
52. Coupland LA, Parish CR. 2014. Platelets, selectins, and the control of tumor metastasis. Semin Oncol. 41:422-434.
53. Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune system. Nat Rev Immunol. 7:255-266.
54. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. 2014. Sialosignaling: Sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta. 1840:2752-2764.
55. Davies LR, Pearce OM, Tessier MB, Assar S, Smutova V, Pajunen M, Sumida M, Sato C, Kitajima K, Finne J, et al. 2012. Metabolism of vertebrate amino sugars with N-glycolyl groups: Resistance of alpha2-8-linked N-glycolylneuraminic acid to enzymatic cleavage. J Biol Chem. 287:28917-28931.
56. Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA. 2005. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res. 65:5750-5760.
57. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, Burton DR, Crispin M, Scanlan CN. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci USA. 107:13800-13805.
58. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. 2013. Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 13:759-771.
59. Frenette PS,Wagner DD. 1996. Adhesion molecules-Part II: Blood vessels and blood cells. N Engl J Med. 335:43-45.
60. Frenette PS, Wagner DD. 1997. Insights into selectin function from knockout mice. Thromb Haemost. 78:60-64.
61. Fukuda MN, Ohyama C, Lowitz K, Matsuo O, Pasqualini R, Ruoslahti E, Fukuda M. 2000. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60:450-456.
62. Gabius HJ. 2015. The magic of the sugar code. Trends Biochem Sci. 40:341.
63. Gay LJ, Felding-Habermann B. 2011. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 11:123-134.
64. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. 2010. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 28:863-867.
65. Gilmour AM, Abdulkhalek S, Cheng TS, Alghamdi F, Jayanth P, O'Shea LK, Geen O, Arvizu LA, Szewczuk MR. 2013. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer. Cell Signal. 25:2587-2603.
66. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, et al. 2014. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 124:1765-1776.
67. Go S, Sato C, Furuhata K, Kitajima K. 2006. Oral ingestion of mannose alters the expression level of deaminoneuraminic acid (KDN) in mouse organs. Glycoconj J. 23:411-421.
68. Go S, Sato C, Yin J, Kannagi R, Kitajima K. 2007. Hypoxia-enhanced expression of free deaminoneuraminic acid in human cancer cells. Biochem Biophys Res Commun. 357:537-542.
69. Gomes AM, Kozlowski EO, Borsig L, Teixeira FC, Vlodavsky I, Pavao MS. 2015. Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: Effect on P-selectin, heparanase, metastasis and cellular recruitment. Glycobiology. 25:386-393.
70. Gomes C, Osorio H, Pinto MT, Campos D, Oliveira MJ, Reis CA. 2013. Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS ONE. 8: e66737.
71. Gottschling S, Jensen K,Warth A, Herth FJ, Thomas M, Schnabel PA,Herpel E. 2013. Stage-specific embryonic antigen-4 is expressed in basaloid lung cancer and associated with poor prognosis. Eur Respir J. 41:656-663.
72. Gout S, Morin C, Houle F, Huot J. 2006. Death receptor-3, a new E-selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res. 66:9117-9124.
73. Gretschel S, Haensch W, Schlag PM, Kemmner W. 2003. Clinical relevance of sialyltransferases ST6GAL-I and ST3GAL-III in gastric cancer. Oncology. 65:139-145.
74. Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell. 140:883-899.
75. Haltiwanger RS, Lowe JB. 2004. Role of glycosylation in development. Annu Rev Biochem. 73:491-537.
76. Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R. 2005. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res. 65:5812-5817.
77. Hata K, Tochigi T, Sato I, Kawamura S, Shiozaki K, Wada T, Takahashi K, Moriya S, Yamaguchi K, Hosono M, et al. 2015. Increased sialidase activity in serum of cancer patients: Identification of sialidase and inhibitor activities in human serum. Cancer Sci. 106:383-389.
78. Hedlund M, Padler-Karavani V, Varki NM, Varki A. 2008. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci USA. 105:18936-18941.
79. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, et al. 2007. N-Glycolylneuraminic acid deficiency in mice: Implications for human biology and evolution. Mol Cell Biol. 27:4340-4346.
80. Hernandez AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, Alfonso S, Rondon T, Suarez E, Vazquez AM, et al. 2008. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol. 181:6625-6634.
81. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, et al. 2014. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15:986-996.
82. Hollingsworth MA, Swanson BJ. 2004. Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer. 4:45-60.
83. Hoos A, Protsyuk D, Borsig L. 2014. Metastatic growth progression caused by PSGL-1-mediated recruitment of monocytes to metastatic sites. Cancer Res. 74:695-704.
84. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, Vlodavsky I, Borsig L. 2007. P-selectin-and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 21:3562-3572.
85. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 82:1242-1246.
86. Huang ZH, Shi L,Ma JW, Sun ZY, Cai H, Chen YX, Zhao YF, Li YM. 2012. A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. J Am Chem Soc. 134:8730-8733.
87. Hudak JE, Canham SM, Bertozzi CR. 2014. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 10:69-75.
88. Ikehara Y, Kojima N, Kurosawa N, Kudo T, Kono M, Nishihara S, Issiki S, Morozumi K, Itzkowitz S, Tsuda T, et al. 1999. Cloning and expression of a human gene encoding an N-acetylgalactosamine-alpha2,6-sialyltransferase (ST6GalNAc I): A candidate for synthesis of cancerassociated sialyl-Tn antigens. Glycobiology. 9:1213-1224.
89. Inoue S, Lin SL, Chang T, Wu SH, Yao CW, Chu TY, Troy FA 2nd, Inoue Y. 1998. Identification of free deaminated sialic acid (2-keto-3-deoxy-Dglycero-D-galacto-nononic acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells. J Biol Chem. 273:27199-27204.
90. Inoue S, Poongodi GL, Suresh N, Chang T, Inoue Y. 2006. Identification and partial characterization of soluble and membrane-bound KDN(deaminoneuraminic acid)-glycoproteins in human ovarian teratocarcinoma PA-1, and enhanced expression of free and bound KDN in cells cultured in mannose-rich media. Glycoconj J. 23:401-410.
91. Ishii A, Ohta M,Watanabe Y, Matsuda K, Ishiyama K, Sakoe K, NakamuraM, Inokuchi J, Sanai Y, Saito M. 1998. Expression cloning and functional characterization of human cDNA for ganglioside GM3 synthase. J Biol Chem. 273:31652-31655.
92. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. 2015. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 125:4010-4016.
93. Jain S, Russell S, Ware J. 2009. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mousemodels. J ThrombHaemost. 7:1713-1717.
94. Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, et al. 2007. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA. 104:9024-9028.
95. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Demoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, et al. 2014. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest. 124:1810-1820.
96. Ju T, Aryal RP, Kudelka MR, Wang Y, Cummings RD. 2014. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 14:63-81.
97. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X. 2006. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology. 16:54-64.
98. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, et al. 2011. Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Res. 71:7683-7693.
99. Julien S, Krzewinski-Recchi MA, Harduin-Lepers A, Gouyer V, Huet G, Le Bourhis X, Delannoy P. 2001. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconj J. 18: 883-893.
100. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M,Williamson RC. 2004. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 22:1944-1948.
101. Kakugawa Y,Wada T, Yamaguchi K, Yamanami H, Ouchi K, Sato I, Miyagi T. 2002. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc Natl Acad Sci USA. 99:10718-10723.
102. Kameda Y, Takahata M, Komatsu M, Mikuni S, Hatakeyama S, Shimizu T, Angata T, Kinjo M, Minami A, Iwasaki N. 2013. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12. J Bone Miner Res. 28:2463-2475.
103. Kannagi R, Cochran NA, Ishigami F, Hakomori S, Andrews PW, Knowles BB, Solter D. 1983. Stage-specific embryonic antigens (SSEA-3 and-4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 2:2355-2361.
104. Kansas GS. 1996. Selectins and their ligands: Current concepts and controversies. Blood. 88:3259-3287.
105. Kawamura S, Sato I, Wada T, Yamaguchi K, Li Y, Li D, Zhao X, Ueno S, Aoki H, Tochigi T, et al. 2012. Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling. Cell Death Differ. 19:170-179.
106. Kawasaki N, Vela JL, Nycholat CM, Rademacher C, Khurana A, van Rooijen N, Crocker PR, Kronenberg M, Paulson JC. 2013. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc Natl Acad Sci USA. 110:7826-7831.
107. Khatib AM, Fallavollita L,Wancewicz EV, Monia BP, Brodt P. 2002. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res. 62:5393-5398.
108. Kim YJ, Borsig L, Han HL, Varki NM, Varki A. 1999. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol. 155: 461-472.
109. Kim YJ, Borsig L, Varki NM, Varki A. 1998. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA. 95:9325-9330.
110. Kim YJ, Kim KS, Do S, Kim CH, Kim SK, Lee YC. 1997. Molecular cloning and expression of human alpha2,8-sialyltransferase (hST8Sia V). Biochem Biophys Res Commun. 235:327-330.
111. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, et al. 2005. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:2130-2135.
112. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. 1998. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 101:877-889.
113. Koseki K,Wada T, Hosono M, Hata K, Yamaguchi K, Nitta K, Miyagi T. 2012. Human cytosolic sialidase NEU2-low general tissue expression but involvement in PC-3 prostate cancer cell survival. Biochem Biophys Res Commun. 428:142-149.
114. Kozlowski EO, Pavao MS, Borsig L. 2011. Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. J Thromb Haemost. 9:1807-1815.
115. Laubli H, Alisson-Silva F, Stanczak MA, Siddiqui SS, Deng L, Verhagen A, Varki N, Varki A. 2014. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs. J Biol Chem. 289:33481-33491.
116. Laubli H, Borsig L. 2009. Heparins attenuate cancer metastasis: Are selectins the link? Cancer Invest. 27:474-481.
117. Laubli H, Borsig L. 2010a. Selectins as mediators of lung metastasis. Cancer Microenviron. 3:97-105.
118. Laubli H, Borsig L. 2010b. Selectins promote tumor metastasis. Semin Cancer Biol. 20:169-177.
119. Laubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, et al. 2014. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc Natl Acad Sci USA. 111:14211-14216.
120. Laubli H, Spanaus KS, Borsig L. 2009. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 114:4583-4591.
121. Laubli H, Stevenson JL, Varki A, Varki NM, Borsig L. 2006. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res. 66:1536-1542.
122. Lee YC, Kaufmann M, Kitazume-Kawaguchi S, Kono M, Takashima S, Kurosawa N, Liu H, Pircher H, Tsuji S. 1999. Molecular cloning and functional expression of two members of mouse NeuAcalpha2,3Galbeta1,3Gal-NAc GalNAcalpha2,6-sialyltransferase family, ST6GalNAc III and IV. J Biol Chem. 274:11958-11967.
123. Lee YC, Kim YJ, Lee KY, Kim KS, Kim BU, Kim HN, Kim CH, Do SI. 1998. Cloning and expression of cDNA for a human Sia alpha 2,3Gal beta 1, 4GlcNA:alpha 2,8-sialyltransferase (hST8Sia III). Arch Biochem Biophys. 360:41-46.
124. Lee M, Lee HJ, Bae S, Lee YS. 2008. Protein sialylation by sialyltransferase involves radiation resistance. Mol Cancer Res. 6:1316-1325.
125. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et al. 2003. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 349:146-153.
126. Ley K. 2003. The role of selectins in inflammation and disease. Trends Mol Med. 9:263-268.
127. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. 2007. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol. 7:678-689.
128. Li J, Guillebon AD, Hsu JW, Barthel SR, Dimitroff CJ, Lee YF, King MR. 2013. Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br J Cancer. 109:3014-3022.
129. Li X, Zhang L, Shao Y, Liang Z, Shao C, Wang B, Guo B, Li N, Zhao X, Li Y, et al. 2011. Effects of a human plasma membrane-associated sialidase siRNA on prostate cancer invasion. Biochem Biophys Res Commun. 416:270-276.
130. Macauley MS, Crocker PR, Paulson JC. 2014. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 14:653-666.
131. Mandal C, Tringali C, Mondal S, Anastasia L, Chandra S, Venerando B, Mandal C. 2010. Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells. Int J Cancer. 126:337-349.
132. Mann B, Klussmann E, Vandamme-Feldhaus V, Iwersen M, Hanski ML, Riecken EO, Buhr HJ, Schauer R, Kim YS, Hanski C. 1997. Low O-acetylation of sialyl-Le(x) contributes to its overexpression in colon carcinoma metastases. Int J Cancer. 72:258-264.
133. Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP. 1995. Differential colon cancer cell adhesion to E-, P-, and L-selectin: Role of mucin-type glycoproteins. Cancer Res. 55:4425-4431.
134. Mannori G, Santoro D, Carter L, Corless C, Nelson RM, Bevilacqua MP. 1997. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol. 151:233-243.
135. Manzi AE, Dell A, Azadi P, Varki A. 1990. Studies of naturally occurring modifications of sialic acids by fast-atom bombardment-mass spectrometry. Analysis of positional isomers by periodate cleavage. J Biol Chem. 265:8094-8107.
136. Manzi AE, Sjoberg ER, Diaz S, Varki A. 1990. Biosynthesis and turnover of O-acetyl and N-acetyl groups in the gangliosides of human melanoma cells. J Biol Chem. 265:13091-13103.
137. McEver RP. 2002. Selectins: Lectins that initiate cell adhesion under flow. Curr Opin Cell Biol. 14:581-586.
138. McEver RP. 2015. Selectins: Initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 107:331-339.
139. Mittal D, GubinMM, Schreiber RD, Smyth MJ. 2014. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 27:16-25.
140. Miyagi T, Wada T, Iwamatsu A, Hata K, Yoshikawa Y, Tokuyama S, Sawada M. 1999. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J Biol Chem. 274:5004-5011.
141. Miyata M, Kambe M, Tajima O, Moriya S, Sawaki H, Hotta H, Kondo Y, Narimatsu H, Miyagi T, Furukawa K, et al. 2011. Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides. Cancer Sci. 102:2139-2149.
142. Miyazaki K, Sakuma K, Kawamura YI, Izawa M, Ohmori K, Mitsuki M, Yamaji T, Hashimoto Y, Suzuki A, Saito Y, et al. 2012. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and-9. J Immunol. 188:4690-4700.
143. Monti E, Bassi MT, Bresciani R, Civini S, Croci GL, Papini N, Riboni M, Zanchetti G, Ballabio A, Preti A, et al. 2004. Molecular cloning and characterization of NEU4, the fourth member of the human sialidase gene family. Genomics. 83:445-453.
144. Monti E, Preti A, Rossi E, Ballabio A, Borsani G. 1999. Cloning and characterization of NEU2, a human gene homologous to rodent soluble sialidases. Genomics. 57:137-143.
145. Mozzi A, Forcella M, Riva A, Difrancesco C, Molinari F, Martin V, Papini N, Bernasconi B, Nonnis S, Tedeschi G, et al. 2015. NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels. Glycobiology. 25:855-868.
146. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A. 2006. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA. 103:7765-7770.
147. Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T, Aoki D. 2006. Expression of NEU3 (plasma membraneassociated sialidase) in clear cell adenocarcinoma of the ovary: Its relationship with T factor of pTNM classification. Oncol Res. 16:289-297.
148. Okajima T, Fukumoto S, Miyazaki H, Ishida H, Kiso M, Furukawa K, Urano T, Furukawa K. 1999. Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J Biol Chem. 274:11479-11486.
149. O'Shea LK, Abdulkhalek S, Allison S, Neufeld RJ, Szewczuk MR. 2014. Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu(R)) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther. 7:117-134.
150. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, et al. 2011. Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 71:3352-3363.
151. Pal S, Bandyopadhyay S, Chatterjee M, Bhattacharya DK, Minto L, Hall AG, Mandal C. 2004. Antibodies against 9-O-acetylated sialoglycans: A potent marker to monitor clinical status in childhood acute lymphoblastic leukemia. Clin Biochem. 37:395-403.
152. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. 2005. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 105:178-185.
153. Pan A, Sun Q, Bernstein AM, Schulze MB, Manson JE, Stampfer MJ, Willett WC, Hu FB. 2012. Red meat consumption and mortality: Results from 2 prospective cohort studies. Arch Intern Med. 172:555-563.
154. Paulson JC, Rearick JI, Hill RL. 1977. Enzymatic properties of beta-D-galactoside alpha2 leads to 6 sialytransferase from bovine colostrum. J Biol Chem. 252:2363-2371.
155. Pearce OM, LaubliH, Bui J, Varki A. 2014.Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Oncoimmunology. 3:e29312.
156. Pearce OM, Laubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. 2014. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci USA. 111:5998-6003.
157. Pham T, Gregg CJ, Karp F, Chow R, Padler-Karavani V, Cao H, Chen X, Witztum JL, Varki NM, Varki A. 2009. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood. 114:5225-5235.
158. Pillai S, Netravali IA, Cariappa A, Mattoo H. 2012. Siglecs and immune regulation. Annu Rev Immunol. 30:357-392.
159. Pinho SS, Reis CA. 2015. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540-555.
160. Polgar J, Matuskova J, Wagner DD. 2005. The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 3:1590-1596.
161. Proshin S, Yamaguchi K, Wada T, Miyagi T. 2002. Modulation of neuritogenesis by ganglioside-specific sialidase (Neu 3) in human neuroblastoma NB-1 cells. Neurochem Res. 27:841-846.
162. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 475:222-225.
163. Recchi MA, Hebbar M, Hornez L, Harduin-Lepers A, Peyrat JP, Delannoy P. 1998. Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer. Cancer Res. 58:4066-4070.
164. Ricardo S, Marcos-Silva L, Pereira D, Pinto R, Almeida R, Soderberg O, Mandel U, Clausen H, Felix A, Lunet N, et al. 2015. Detection of glycomucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol. 9:503-512.
165. Romero P, Coukos G. 2014. Cancer immunotherapy: Hype or ripe? [corrected]. Eur J Immunol. 44:318-320.
166. Rutishauser U. 2008. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat Rev Neurosci. 9:26-35.
167. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708-712.
168. Samraj AN, Laubli H, Varki N, Varki A. 2014. Involvement of a non-human sialic acid in human cancer. Front Oncol. 4:33.
169. Samraj AN, Pearce OM, Laubli H, Crittenden AN, Bergfeld AK, Banda K, Gregg CJ, Bingman AE, Secrest P, Diaz SL, et al. 2015. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci USA. 112:542-547.
170. Samyn-Petit B, Krzewinski-Recchi MA, Steelant WF, Delannoy P, Harduin-Lepers A. 2000. Molecular cloning and functional expression of human ST6GalNAc II. Molecular expression in various human cultured cells. Biochim Biophys Acta. 1474:201-211.
171. Sasaki K, Kurata K, Kojima N, Kurosawa N, Ohta S, Hanai N, Tsuji S, Nishi T. 1994. Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase). J Biol Chem. 269:15950-15956.
172. Schauer R. 1970a. [Biosynthesis of N-acetyl-O-acetylneuraminic acids. I. Incorporation of (14C) acetate into sections of the submaxillary salivary gland of ox and horse]. Hoppe Seylers Z Physiol Chem. 351:595-602.
173. Schauer R. 1970b. [Biosynthesis of N-acetyl-O-acetylneuraminic acids. II. Substrate and intracellular localization of bovine acetyl-coenzyme A: N-acetylneuraminate-7-and 8-O-acetyltransferase]. Hoppe Seylers Z Physiol Chem. 351:749-758.
174. Schauer R. 2000. Achievements and challenges of sialic acid research. Glycoconj J. 17:485-499.
175. Scheidegger EP, Sternberg LR, Roth J, Lowe JB. 1995. A human STX cDNA confers polysialic acid expression in mammalian cells. J Biol Chem. 270:22685-22688.
176. Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, Miescher S, Simon HU, Pashov A, Vassilev T, et al. 2015. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med. 7:269ra261.
177. Schwarz F, Fong JJ, Varki A. 2015. Human-specific evolutionary changes in the biology of siglecs. Adv Exp Med Biol. 842:1-16.
178. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. 2005. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 65:4645-4652.
179. Seberger PJ, Chaney WG. 1999. Control of metastasis by Asn-linked, beta1-6 branched oligosaccharides in mouse mammary cancer cells. Glycobiology. 9:235-241.
180. Senda M, Ito A, Tsuchida A, Hagiwara T, Kaneda T, Nakamura Y, Kasama K, KisoM, Yoshikawa K, Katagiri Y, et al. 2007. Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: Downregulation of ST6GalNAc VI in renal cancers. Biochem J. 402:459-470.
181. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP. 2011. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 118:4015-4023.
182. Shen Y, Kohla G, Lrhorfi AL, Sipos B, Kalthoff H, Gerwig GJ, Kamerling JP, Schauer R, Tiralongo J. 2004. O-Acetylation and de-O-acetylation of sialic acids in human colorectal carcinoma. Eur J Biochem. 271:281-290.
183. Shiozaki K, Yamaguchi K, Takahashi K, Moriya S, Miyagi T. 2011. Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. J Biol Chem. 286:21052-21061.
184. Shirure VS, Liu T, Delgadillo LF, Cuckler CM, Tees DF, Benencia F, Goetz DJ, Burdick MM. 2015. CD44 variant isoforms expressed by breast cancer cells are functional E-selectin ligands under flow conditions. Am J Physiol Cell Physiol. 308:C68-C78.
185. Smutova V, Albohy A, Pan X, Korchagina E, Miyagi T, Bovin N, Cairo CW, Pshezhetsky AV. 2014. Structural basis for substrate specificity of mammalian neuraminidases. PLoS ONE. 9:e106320.
186. Stevenson JL, Choi SH, Varki A. 2005. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 11:7003-7011.
187. Stevenson JL, Varki A, Borsig L. 2007. Heparin attenuates metastasis mainly due to inhibition of P-and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res. 120(Suppl. 2):S107-S111.
188. Stubke K, Wicklein D, Herich L, Schumacher U, Nehmann N. 2012. Selectindeficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett. 321:89-99.
189. Subramaniam M, Frenette PS, Saffaripour S, Johnson RC, Hynes RO, Wagner DD. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood. 87:1238-1242.
190. Sumida M, Hane M, Yabe U, Shimoda Y, Pearce OM, Kiso M, Miyagi T, Sawada M, Varki A, Kitajima K, et al. 2015. Rapid trimming of cell surface polysialic acid (PolySia) by exovesicular sialidase triggers release of preexisting surface neurotrophin. J Biol Chem. 290:13202-13214.
191. Tachibana H, Taniguchi K, Ushio Y, Teruya K, Osada K, Murakami H. 1994. Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody. Cytotechnology. 16:151-157.
192. Takahashi K, Hosono M, Sato I, Hata K, Wada T, Yamaguchi K, Nitta K, Shima H, Miyagi T. 2015. Sialidase NEU3 contributes neoplastic potential on colon cancer cells as a key modulator of gangliosides by regulating Wnt signaling. Int J Cancer. 137:1560-1573.
193. Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. 2013. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology. 23:178-187.
194. Takashima S, Ishida HK, Inazu T, Ando T, Ishida H, Kiso M, Tsuji S, Tsujimoto M. 2002. Molecular cloning and expression of a sixth type of alpha 2,8-sialyltransferase (ST8Sia VI) that sialylates O-glycans. J Biol Chem. 277:24030-24038.
195. Takashima S, Tsuji S, Tsujimoto M. 2002. Characterization of the second type of human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Galbeta 1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human sialyltransferase genes. J Biol Chem. 277:45719-45728.
196. Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, LiM, Yanagihara K, Nakayama J, Fujimoto I, Ikenaka K, et al. 2000. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res. 60:3072-3080.
197. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA. 100:12045-12050.
198. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V, et al. 2010. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J Exp Med. 207:1637-1646.
199. Thomas SN, Schnaar RL, Konstantopoulos K. 2009. Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: Comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol. 296:C505-C513.
200. Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ. 2015. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chem Commun (Camb). 51:10214-10217.
201. Thurin J, Herlyn M, Hindsgaul O, Stromberg N, Karlsson KA, Elder D, Steplewski Z, Koprowski H. 1985. Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. J Biol Chem. 260:14556-14563.
202. Topalian SL, Drake CG, Pardoll DM. 2015. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell. 27:450-461.
203. Tringali C, Cirillo F, Lamorte G, Papini N, Anastasia L, Lupo B, Silvestri I, Tettamanti G, Venerando B. 2012. NEU4L sialidase overexpression promotes beta-catenin signaling in neuroblastoma cells, enhancing stem-like malignant cell growth. Int J Cancer. 131:1768-1778.
204. Tringali C, Lupo B, Anastasia L, Papini N, Monti E, Bresciani R, Tettamanti G, Venerando B. 2007. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J Biol Chem. 282:14364-14372.
205. Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G, Venerando B. 2012. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling beta1 integrin internalization and recycling. J Biol Chem. 287:42835-42845.
206. Tringali C, Silvestri I, Testa F, Baldassari P, Anastasia L, Mortarini R, Anichini A, Lopez-Requena A, Tettamanti G, Venerando B. 2014. Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer. 14:560.
207. Tsuchida A, Okajima T, Furukawa K, Ando T, Ishida H, Yoshida A, Nakamura Y, Kannagi R, Kiso M, Furukawa K. 2003. Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. J Biol Chem. 278:22787-22794.
208. Uemura T, Shiozaki K, Yamaguchi K, Miyazaki S, Satomi S, Kato K, Sakuraba H, Miyagi T. 2009. Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene. 28:1218-1229.
209. Ueno S, Saito S,Wada T, Yamaguchi K, Satoh M, Arai Y, Miyagi T. 2006. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility. J Biol Chem. 281:7756-7764.
210. Varki A. 1997. Selectin ligands:Will the real ones please stand up? J Clin Invest. 99:158-162.
211. Varki A. 2001. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol. (Suppl. 33):54-69.
212. Varki A. 2007. Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood. 110:1723-1729.
213. Varki A. 2011. Since there are PAMPs and DAMPs, there must be SAMPs? Glycan "self-associated molecular patterns" dampen innate immunity, but pathogens can mimic them. Glycobiology. 21:1121-1124.
214. Varki A, Lowe JB. 2009. Biological roles of glycans. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of Glycobiology. New York: Cold Spring Harbor.
215. Varki NM, Varki A. 2007. Diversity in cell surface sialic acid presentations: Implications for biology and disease. Lab Invest. 87:851-857.
216. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FG, van Kamp GJ, Schol DJ, Reis CA, Price MR, et al. 2000. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer. 86:702-712.
217. Wada T, Hata K, Yamaguchi K, Shiozaki K, Koseki K, Moriya S, Miyagi T. 2007. A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells. Oncogene. 26:2483-2490.
218. Wada T, Yoshikawa Y, Tokuyama S, Kuwabara M, Akita H, Miyagi T. 1999. Cloning, expression, and chromosomal mapping of a human ganglioside sialidase. Biochem Biophys Res Commun. 261:21-27.
219. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. 2003. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 112:853-862.
220. Wang X, Mitra N, Cruz P, Deng L, Program NCS, Varki N, Angata T, Green ED, Mullikin J, Hayakawa T, et al. 2012. Evolution of siglec-11 and siglec-16 genes in hominins. Mol Biol Evol. 29:2073-2086.
221. Wang F, Xie B,Wang B, Troy FA II. 2015. LC-MS/MS glycomic analyses of free and conjugated forms of the sialic acids, Neu5Ac, Neu5Gc and KDN in human throat cancers. Glycobiology. 25:1362-1374.
222. Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Sturzl M, et al. 2012. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell. 22:91-105.
223. Wu X, Ragupathi G, Panageas K, Hong F, Livingston PO. 2013. Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway. Clin Cancer Res. 19:4728-4739.
224. Yabu M, Korekane H, Hatano K, Kaneda Y, Nonomura N, Sato C, Kitajima K, Miyamoto Y. 2013. Occurrence of free deaminoneuraminic acid (KDN)-containing complex-type N-glycans in human prostate cancers. Glycobiology. 23:634-642.
225. Yamamoto K, Takahashi K, Shiozaki K, Yamaguchi K, Moriya S, Hosono M, Shima H, Miyagi T. 2015. Potentiation of epidermal growth factormediated oncogenic transformation by sialidase NEU3 leading to Src activation. PLoS ONE. 10:e0120578.
226. Yasmin-Karim S, King MR, Messing EM, Lee YF. 2014. E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget. 5:12097-12110.
227. Yeh J, Cummings RD. 1997. Differential recognition of glycoprotein acceptors by terminal glycosyltransferases. Glycobiology. 7:241-251.